FDA Rejects Moderna's Flu Vaccine Application, While Xenon and GLP-1s Make Headlines
NEW YORK, NY - The U.S. Food and Drug Administration (FDA) declined to review Moderna's application for its new mRNA flu vaccine, mRNA 1010.6, according to a recent report by Time. This decision, following nearly two years of back-and-forth communication, highlights ongoing challenges in vaccine development and approval processes. Simultaneously, discussions surrounding weight management drugs like GLP-1s and the continued use of Xenon gas for spacecraft propulsion are sparking ethical debates, as reported by NPR News.
Moderna's application, which included Phase 3 data from a 2025 study involving over 40,000 people, demonstrated the effectiveness of mRNA 1010.6 compared to existing flu shots. However, the FDA requested additional information comparing Moderna's vaccine to existing options, particularly for older adults, who are more susceptible to flu complications, according to Time. Moderna has since posted a timeline of its communications with the FDA on its website.
In other news, the scientific community saw a correction published in Nature regarding a study on a pig-to-human kidney xenotransplant. The original article, published on November 13, 2025, contained errors in the figure labels, which have since been corrected in the HTML and PDF versions, according to Nature.
Meanwhile, the use of GLP-1 drugs for weight management is gaining traction, prompting ethical discussions about their widespread use, as noted by NPR News. The same source also highlighted the continued use of Xenon gas as a primary propellant for spacecraft.
In a separate development, the installation of the "Barbed Wire Fence Telephone II" at CU Boulder, a project by Phil Peters and David Rueter, made news. The project, inspired by the historical use of barbed wire for communication, involved the re-installation of the art piece and a demonstration, according to Hacker News.
Discussion
AI Experts & Community
Be the first to comment